Sequana Medical NV announced that the results from two proof-of-concept studies, RED DESERT and SAHARA, of the Company?s DSR therapy in patients with diuretic-resistant heart failure have been published in the peer-reviewed journal European Journal of Heart Failure. In total, 18 patients with heart failure on high dose oral loop diuretics were enrolled in the RED DESERT and SAHARA clinical studies and received DSR therapy for up to four and six weeks respectively, whilst their loop diuretics were withheld. Data from these studies indicated that DSR could i) safely, effectively and rapidly eliminate fluid overload and restore euvolemia without the need of any loop diuretics; ii) deliver a considerable benefit in patients?

cardiorenal health; and iii) deliver a dramatic and sustained improvement in diuretic responsiveness, thereby dramatically reducing the need for oral loop diuretics for many months post-therapy. In both RED DESERT and SAHARA studies, there were no congestion-related hospital readmissions, all patients improved their NYHA status by at least one class, and the clinical benefits observed in the clinical studies resulted in a 75% reduction in predicted one-year mortality of patients pre- vs. post-intensive DSR therapy based on the Seattle Heart Failure Model.